Splenectomy for hereditary spherocytosis: complete, partial or not at all?
| Autor: | Maddalena Casale, Silverio Perrotta |
|---|---|
| Přispěvatelé: | Casale, Maddalena, Perrotta, Silverio |
| Rok vydání: | 2011 |
| Předmět: |
Hemolytic anemia
Pediatrics medicine.medical_specialty IgM memory Time Factors Anemia medicine.medical_treatment Spherocytosis Splenectomy Spleen Spherocytosis Hereditary immunization Hereditary spherocytosis Risk Factors medicine Humans Vascular Diseases business.industry Deferasirox hereditary spherocytosi Hematology medicine.disease Hemolysis medicine.anatomical_structure Immunology business deferasirox medicine.drug |
| Zdroj: | Expert review of hematology. 4(6) |
| ISSN: | 1747-4094 |
| Popis: | Hereditary spherocytosis (HS) is an hematologic disorder, common in the Northern European population, which is characterized by hemolytic anemia and splenomegaly. The pathophysiological bedrock of HS consists of the retention and damage of abnormal red cells, caused by an intrinsic erythrocyte membrane defect. Hemolysis within the spleen is the main detrminant of erythrocyte destruction in patients with HS. Splenectomy removes the primary ?graveyard? for spherocytes and, thus, eliminates anemia and hyperbilirubinemia and lowers the high reticulocyte number to nearly normal levels. Spleen removal is an effective therapeutic option but it is not without risks. The incidence and public health impact of spleen surgery in children with HS is substantial. Unfortunately, splenectomy is sometimes recommended erroneously for young children who have a mild clinical phenotype or is performed without relying on careful assessment of the risks and benefits. This article aims to present criticism and address controversy about HS management. Unclear and still controversial issues are tackled according to the author?s personal viewpoint, because strong evidence in different aspects of HS management is lacking. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|